Uls Santa Maria Hosp. Santa Maria

Lisbon 1769 001

5 studies enrolling now · 13 studies all time

What they study most

Arthritis, Psoriatic, Bladder Cancer, Carcinoma, Squamous Cell, Colitis, Ulcerative, Crohn Disease, Depressive Disorder, Major, Leukemia, Myeloid, Acute, Lupus Erythematosus, Systemic, Metastatic Castration-sensitive Prostate Cancer, Prostatic Neoplasms, Sjogrens Syndrome, Squamous Cell Carcinoma of Head and Neck

Studies at this site

• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — Recruiting now
• JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC — Recruiting now
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — Recruiting now
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer — Recruiting now
• Nipocalimab in Moderate to Severe Sjogren's Disease — Running, not enrolling
• A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease — Running, not enrolling
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) — Running, not enrolling